New studies link pregnancy infections to autism and show potential skin healing drug
New studies link pregnancy infections to autism and show potential skin healing drug
Updated at: September 24, 2026 at 03:30 AM
Recent scientific breakthroughs are bridging the gap between immunology and neurology, offering new insights into autism spectrum disorder (ASD).
Researchers are focusing on Maternal Immune Activation, where infections during pregnancy trigger an immune response.
This release of pro-inflammatory proteins, specifically Interleukin-17a (IL-17a), can cross the placental barrier and influence fetal brain development.
Interestingly, high levels of IL-17a are also linked to chronic skin conditions like psoriasis.
This connection has led scientists to explore whether existing dermatological drugs, which inhibit IL-17a, might help treat certain autism-related symptoms.
Early studies using animal models have shown promise in reducing social and behavioral challenges.
However, experts urge caution; while these findings are encouraging, ASD is a highly complex, heterogeneous condition with various genetic and environmental influences.
The research does not suggest a cure, but it represents a shift toward precision medicine, where scientists aim to target specific biological pathways rather than just managing symptoms.
As investigators continue to study the systemic roots of brain development, this intersection of immunology and neurology remains one of the most exciting areas of modern medical research.
